Ranbaxy announces launch of Letrozole Tablets in UK, Romania and France

Ranbaxy Laboratories Limited (Ranbaxy) today announced the launch of Letrozole Tablets 2.5 mg in UK, Romania and France, on Day-1. Letrozole is the bio equivalent of Femara, the innovator product of Novartis, that has a market size of USD 58 Mn in UK (Source: IMS 2010), USD 95 Mn in France (Source: GERS May 2011) and USD 5.5 Mn in Romania (Source: Cegedim2010).

“We are pleased to introduce Letrozole at the earliest available opportunity in UK, Romania & France with a view to broadening access to medication. The product will be offered through pharmacies, retail and wholesale stores with immediate effect and will benefit the healthcare system in these EU markets.”

Commenting on the Day-1 launch, Mr. Debashis Dasgupta, Regional Director, Ranbaxy, Europe, said,

"We are pleased to introduce Letrozole at the earliest available opportunity in UK, Romania & France with a view to broadening access to medication. The product will be offered through pharmacies, retail and wholesale stores with immediate effect and will benefit the healthcare system in these EU markets."

Letrozole is an Antineoplastics, indicated for the treatment of breast cancer.

Ranbaxy's subsidiary companies, Ranbaxy (UK) Limited, Terapia Ranbaxy and Ranbaxy Pharmacie Generiques will be marketing this product in UK, Romania and France respectively.